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Abstract
The DNA cutting and joining reactions of HIV-1 integration are catalyzed by integrase (IN), a viral protein that functions as a
tetramer bridging the two viral DNA ends (intasome). Two major obstacles for biochemical and structural studies of HIV-1
intasomes are 1) the low efficiency of assembly with oligonucleotide DNA substrates, and 2) the non-specific aggregation of
both intasomes and free IN in the reaction mixture. By fusing IN with a small non-specific DNA binding protein, Sulfolobus
solfataricus chromosomal protein Sso7d (PDB: 1BNZ), we have engineered a highly soluble and hyperactive IN. Unlike wild-
type IN, it efficiently catalyzes intasome assembly and concerted integration with oligonucleotide DNA substrates. The
fusion IN protein also functions to integrate viral reverse transcripts during HIV-infection. The hyperactive HIV-1 IN may
assist in facilitating future biochemical and structural studies of HIV-1 intasomes. Understanding the mechanistic basis of the
Sso7d-IN fusion protein could provide insight into the factors that have hindered biophysical studies of wild-type HIV-1 IN
and intasomes.
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Introduction
Integration of retroviral DNA into the host chromosomal DNA
is an essential step in the retroviral replication cycle (reviewed in
[1]). The newly synthesized viral DNA is initially blunt ended, yet
prior to integration into cellular DNA it must be processed by the
removal of two nucleotides from each 39 end. The 39 end
processing reaction exposes the 39 hydroxyl groups that are used in
the subsequent attack of phosphodiester bonds at the site of
integration into host chromosomal DNA within the nucleus during
the DNA strand transfer reaction. In the case of HIV, the sites of
insertion on the two target DNA strands are separated by 5 bp,
resulting in a 5 bp duplication of target DNA sequence flanking
the integrated provirus upon repair of the integration intermedi-
ate.
Under most reaction conditions HIV-1 integrase (IN) predom-
inantly catalyzes a half-site reaction in which only a single viral
DNA end is joined to one strand of target DNA, rather than the
two-ended reaction that is required for productive integration. In
contrast, preintegration complexes (PICs) isolated from infected
cells exclusively carry out two-end integration in vitro. Improved
reaction conditions support concerted integration [2–4], but the
efficiency is low and both the substrates and products aggregate.
Concerted integration proceeds through a series of stable
nucleoprotein complexes, or intasomes [5]. First, a tetramer of
IN bridges the pair of newly reverse-transcribed viral DNA ends to
form the Stable Synaptic Complex (SSC). Processing of the viral
DNA ends converts the SSC to the cleaved intasome (CI) [6] or
cleaved donor complex (CDC) [7]. Next, subsequent to nuclear
import, the CI captures a target DNA and covalently joins viral to
target DNA. The product DNA remains associated with the IN
tetramer in a stable complex called the Strand Transfer Complex
(STC). IN inhibitors such as Raltegravir and Dolutegravir
recognize intasomes rather than free IN protein [8], so high
resolution structures of intasomes are needed to understand the
atomic details of the mechanism of inhibition and evolution of
resistance. To date there are no high-resolution structures of HIV
intasomes, although structures of the closely related Prototype
Foamy Virus (PFV) intasomes have been determined [6,9,10]. The
PFV structures serve as an excellent guide to model the active site
of HIV intasomes [11,12], but sequence divergence makes
modeling less reliable outside the immediate vicinity of the active
site.
The major obstacles to high-resolution structural studies of HIV
intasomes are: 1) the low efficiency of assembly with oligonucle-
otide DNA substrates, and 2) non-specific aggregation of both
intasomes and free IN in the reaction mixture. In contrast, PFV
intasomes are soluble and monodisperse at high concentration and
are efficiently assembled with oligonucleotide DNA [10,13]. A
striking feature of PFV IN is the presence of an extra domain, the
N-terminal extension domain (NED), which interacts with viral
DNA in the PFV intasome structures. We therefore tested whether
fusing non-specific DNA binding domains to the N-terminus of
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IN. One of the domains we tested, Sulfolobus solfataricus
chromosomal protein Sso7d (PDB: 1BNZ), resulted in a hyperac-
tive IN protein. Unlike wild-type IN, it efficiently catalyzes
intasome assembly and concerted integration with oligonucleotide
DNA substrates in vitro. The intasomes are also much more
soluble than those assembled with the wild-type protein. The
hyperactive HIV IN will facilitate future biochemical and
structural studies of HIV intasomes.
Materials and Methods
DNA substrates and recombinant DNA construction
The oligonucleotide viral DNA substrates used in this work
contained 10 bp of a GC rich motif (AGCGTGGGCG) at the 59
end, followed by U5 DNA sequence from the long terminal repeat
(LTR) terminus. Double strand pre-processed DNA substrates
were: U5-19, AGCGTGGGCGTCTCTAGCA; U5-21, AGCG-
TGGGCGAATCTCTAGCA; U5-23, AGCGTGGGCGAAA-
ATCTCTAGCA; U5-25, AGCGTGGGCGGGAAAATCTC-
TAGCA; U5-27, AGCGTGGGCGGTGGAAAATCTCTAGC-
A; U5-29, AGCGTGGGCGGTGTGGAAAATCTCTAGCA;
U5-33, AGCGTGGGCGGTCAGTGTGGAAAATCTCTAGC-
A; U5-37, AGCGTGGGCGTTTAGTCAGTGTGGAAAAT-
CTCTAGCA; U5-41, AGCGTGGGCGCCCTTTTAGTCAG-
TGTGGAAAATCTCTAGCA.
U5-25 was used for the experiments, unless otherwise noted.
Fluorescent DNA substrates were prepared by attaching 6-FAM
fluorophor at the 59 ends of the above oligonucleotides.
Oligonucleotides were purchased from Integrated DNA Technol-
ogies (Coralville, Iowa). An N-terminal His-tagged Sso7d fusion to
the HIV-1 IN sequence (Sso7d-IN) was synthesised by GenScript
(Piscataway, NJ) in pET-28a. Various lengths of glycine linker
were introduced between the Sso7d and IN domains. Sso7d-IN
Figure 1. Sso7d-IN is a hyperactive IN. A, Schematic of the IN fusion proteins. NED, N-terminal extension domain NTD, N-terminal domain; CCD,
catalytic core domain; CTD, C-terminal domain. B, Comparison of the solubilities of wild-type HIV-1 IN and Sso7d-IN. Proteins were incubated at the
indicated NaCl concentrations in 20 mM HEPES pH 7.5, 10% glycerol, 5 mM DTT and 1 mM EDTA, centrifuged and the supernatants and pellets were
analyzed by SDS PAGE. C, Schematic of the in vitro integration reaction with a double stranded oligonucelotide mimicking viral LTR-U5 and a circular
target DNA. D, Strand transfer reaction carried with either wild-type HIV-1 IN or Sso7d-IN with an 11 amino acid linker and a fluorescently labeled viral
DNA substrate (U5-25) in 20 mM HEPES pH 7.5, 10 mM DTT, 5 mM MgCl2,4mM ZnCl2, 100 mM NaCl, 300 ng pGEM-9zf and 0.5 mM viral DNA
substrate. The position of concerted and half-site integration products is indicated. The same gel was visualized by either ethidium bromide staining
(left panel) or a Typhoon 8600 fluorescence scanner (right panel).
doi:10.1371/journal.pone.0105078.g001
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work unless otherwise noted. A DNA binding deficient mutant,
Sso7dmut, harbored two point mutations, W24A and R43E. Vpr
fusion (Vpr-IN) constructs were prepared by insertion of Sso7d-IN
or Sso7dmut-IN DNA into pLR2P-Vpr vector DNA between the
BamHI and XhoI sites; the constructs maintained the upstream
PR cleavage site IRKVL/FLDGI.
Protein expression and purification
His-tagged wild-type IN and Sso7d-IN were expressed and
purified essentially as described [5] with minor modifications.
Briefly, the IN was expressed in E. coli BL21(DE3) and the cells
were lysed in buffer containing 20 mM Hepes pH 7.5, 10%
glycerol, 2 mM 2-mercaptoethanol, 20 mM imidazole and 1 M
NaCl. The protein was purified by nickel-affinity chromatography
and the His-tag was removed with thrombin. Aggregated protein
was removed by gel filtration on a Hiload 26/60 Superdex-200
column (GE Healthcare) equilibrated with 20 mM Hepes pH 7.5,
10% glycerol, 5 mM DTT, 1 mM EDTA and 1 M NaCl. The
protein was concentrated using an Amicon centrifugal conten-
trator (EMD Millipore) as necessary, flash-frozen in liquid nirogen
and stored at 280uC.
Figure 2. Optimization of reaction conditions with Sso7d-IN and oligonucleotide DNA substrates. Concerted integration bands are
indicated with arrows. A, Effect of donor DNA length. The reactions were carried with 1 mM Sso7d-IN (Gly-11) and 0.5 mM viral DNA substrate
containing a ‘‘GC rich’’ motif in 20 mM HEPES pH 7.5, 10 mM DTT, 5 mM MgCl2,4mM ZnCl2, 100 mM NaCl, and 300 ng pGEM-9zf. B, Reactions were
carried with 1 mM Sso7d-IN differing in the length of the glycine linker. C, Concerted integration under optimized conditions. The ratio of Sso7d-IN
(Gly-11) to donor DNA (U5-25) was kept constant at 2:1. Sso7d-IN concentrations are 0.4 mM (lane 1), 1.0 mM (lane 2), 2.0 mM (lane 3), 4.0 mM (lane 4)
and 8.0 mM (lane 5). 25% glycerol was included in the reaction buffer. The DNA smear (S) below the linear concerted integration product results from
multiple integrations into the same target DNA (depicted in D).
doi:10.1371/journal.pone.0105078.g002
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IN (1 mM, unless otherwise noted) and 0.5 mM viral DNA
substrate were preincubated on ice in 20 mM HEPES pH 7.5,
25% glycerol, 10 mM DTT, 5 mM MgCl2,4mM ZnCl2, and
100 mM NaCl in a 20 ml reaction volume. 300 ng of target
plasmid DNA pGEM-9zf was then added and the reaction was
initiated by transfer to 37uC and incubation for 1 hr. For
integration product analysis, the reactions were stopped by
addition of SDS and EDTA to 0.2% and 10 mM, respectively,
together with 5 mg of proteinase K. Incubation was continued at
37uC for a further 1 hr. The DNA was then recovered by ethanol
precipatation and subjected to electrophoresis in a 1.5% agarose
gel in 1x TBE buffer. DNA was visualized either by ethidium
bromide staining or by fluorescence using a Typhoon 8600
fluorescence scanner (GE Healthcare). Intasome assembly was
carried out in the same way except that no target DNA was added
and CaCl2 was substituted for MgCl2. For electrophoretic mobility
shift assays of intasomes (EMSA), the reaction was stopped after
1 hr incubation at 37uC by chilling on ice and addition of 10 mg/
ml heparin. A 2.5 ml aliquot was subjected to electrophoresis on a
3.0% low melting 1x TBE agarose gel (SeaKem LE agarose)
containing 10 mg/ml heparin. Integration products were se-
quenced as described [14]. Briefly, linear DNA corresponding to
concerted integration products was isolated from an agarose gel
and ligated to the Tn5 aminoglycoside-39-O-phosphotransferase
(kanamycin resistance cassette) gene. The DNA was then
transformed into E. coli, and the plasmids were recovered from
kanamycin resistant colonies. Plasmids with the expected correct
size were sequenced and analyzed.
Size-exclusion chromatography of intasomes
500 mM NaCl was added to scaled-up intasome assembly
reaction mixtures (100 ml). After incubation at RT for 15 min, the
mixture was centrifuged at 15,000 g for 15 min and the
supernatant was concentrated to 50 ml using a micro concentrator
(Satorius Stedim Biotech) and loaded onto a Superdex 200 PC
3.2/30 gel filtration column (GE Healthcare) equlibrated with
20 mM HEPES pH 7.5, 20% glycerol, 5 mM DTT and 500 mM
NaCl. The flow rate was 40 ml/min and the fraction size was
50 ml. Fractions were assayed for integration activity. Briefly, 20 ml
of each fraction was added to a 80 ml reaction mixture containing
20 mM HEPES pH 7.5, 25% glycerol, 10 mM DTT, 5 mM
MgCl2,4 mM ZnCl2, and 300 ng of pGEM-9zf. The NaCl
concentration was adjusted to 100 mM. Integration products were
analyzed as described above.
Infectivity assay for Sso7d-IN function
The infectivity assay is based on the ability of IN expressed as a
Vpr fusion protein to trans-complement virus lacking a functional
integrase in a single round of infection. Plasmids pNLX.Luc.R-
[15], pN/N.Luc(R-) [15], and pNLX.Luc.R-DIN [16] expressed
single-round HIV-1NL4-3 carrying wild-type IN, D64N/D116N IN
active site mutations, or a stop codon between the RT and IN
boundary, respectively. Plasmid pRL2PVpr-IN expressed Vpr
fused to the IN protein from HIV-1SG3 [17]. The D64A missense
mutation was introduced into the IN coding region of pRL2PVpr-
IN using PCR-directed mutagenesis. pRL2PVpr-IN was modified
by replacing the coding sequence of SG3 IN with that of NL4-3
IN. The coding sequence for Sso7d was inserted into each plasmid
so as the fuse Sso7d to the N-terminus of IN with a 11 aa glycine
linker. Plasmid pCG-VSV-G [15] was used to express the vesicular
stomatitis virus G (VSV-G) glycoprotein.
HEK293T cells were grown in Dulbecco’s modified Eagle
medium supplemented to contain 10% (v/v) fetal bovine serum,
100 IU/mL penicillin, and 100 mg/mL streptomycin. Pseudovir-
ions harboring transcomplemented IN were constructed by co-
transfecting HEK293T cells with pRL2PVpr-IN expression
plasmids as described [16]. Cell-free supernatants were measured
for p24 content utilizing a commercial p24 ELISA kit (Advanced
Biosciences Laboratories), and SupT1 T cells were infected with
p24-normalized levels of virus as described [16]. Raltegravir
(RAL; 10 mM), which was obtained from the National Institutes of
Health AIDS Research and Reference Reagent Program, was
added to target cells at the time of infection.
Supernatants for immunoblotting were pelleted via ultracentri-
fugation at 4uC for 2 h in a Beckman SW41 rotor at 32,000 rpm.
Pelleted virions were lysed in 40 ml SDS/PAGE sample buffer
[0.3125 M Tris-HCl pH 6.8, 2% SDS, 10% (wt/vol) glycerol, 5%
(wt/vol) 2-mercaptoethanol, 0.001% bromophenol blue, 0.1 M
dithiothreitol], boiled for 5 min, and p24-normalized levels of viral
lysates were fractionated by SDS/PAGE. IN and p24 were
Figure 3. Sequence analysis of concerted integration products.
A, Cone presentation of target duplication size distribution or deletions
in concerted integrants. 36 clones contained a 5 bp duplication. 10
clones contained a short terminal deletion, likely resulting from
contaminating DNA from the smear below the concerted integration
product. B, Weblogo representing nucleotide base frequencies at the
junction of concerted integration products (n=72). The arrow indicates
the middle position of the 5 bp target site duplication. Alignment of
integration site revealed a weak consensus target sequence (GTA/TAC).
The overall height of the stack indicates the sequence conservation at
that position, while the height of symbols within the stack indicates the
relative frequency of each nucleotide at that position. The figure was
created by WebLogo.
doi:10.1371/journal.pone.0105078.g003
Engineered Hyperactive HIV-1 Integrase
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e105078detected using mouse antibodies 8E5 [18] and anti-HIV-1 p24
(Abcam) at 1:5,000 and 1:1,000 dilution, respectively. Horseradish
peroxidase-conjugated secondary antibodies (Dako) were used at
1:10,000.
Results
Construction of a hyperactive IN mutant
PFV IN has several advantages over HIV IN that make it more
amenable to structural studies. The protein is soluble in solution
and remains so when complexed viral DNA ends in the SSC
[10,13]. Furthermore, it assembles SSCs and is highly active with
short oligonucleotide viral DNA substrates. One major difference
between HIV IN and PFV IN is the presence of the extra NED
that binds DNA. Since other attempts to improve the properties of
HIV IN by mutagenesis have been largely unsuccessful, we
decided to take a long-shot approach of fusing other non-specific
DNA binding domains to the N-terminus of HIV IN to make it
more similar to the PFV enzyme (Figure 1A). We screened more
than 30 DNA binding domains, including the PFV NED, zinc
finger domains, pur repressor DNA binding domains, poxvirus
type IB topoisomerase DNA binding domains, and Sso7d (S.
solfataricus chromosomal protein). As expected, most of fusion
proteins exhibited worse behavior and lower activity than the wild-
type IN. In contrast, we found that HIV IN fused with Ssod7
behaved much better than wild-type IN and was predominantly
monomeric under conditions where wild-type is extensively
aggregated (data not shown). Sso7d is a small (,7,000 KDa),
chromosomal protein from the hyperthermophilic archaebacteria
S. solfataricus. It binds to DNA non-specifically and the structure
in complex with DNA has been solved [19]. Fusion of this domain
to other proteins has previously been shown to confer interesting
properties, including increasing the processivity of DNA polymer-
ases [20].
Sso7d - HIV IN is competent for highly efficient concerted
integration in vitro
Wild-type IN has very low solubility in physiological buffer
conditions (150 mM NaCl). In order to keep it soluble, it is usually
stored in high salt (such as 1 M NaCl). We first compared the
solubility of Sso7d-IN protein with that of wild-type. The same
amount of each protein (3 mM) was incubated in 20 mM HEPES
pH 7.5, 10% glycerol, 5 mM DTT and 1 mM EDTA in the
presence of NaCl ranging from 50 mM to 1 M at room
temperature for 30 min. After centrifugation at 15,000 g for
15 min, the soluble protein in the supernatant and the insoluble
protein in the pellet were analyzed by SDS-PAGE. The results are
shown in Figure 1B. Sso7d-IN exhibited much better solubility
than wild-type IN, remaining soluble even at 150 mM and
100 mM NaCl conditions. We next analyzed the ability of Sso7d-
IN to catalyze concerted DNA integration with short (25 bp)
oligonucleotide viral DNA substrates containing a 6-FAM
fluorophore and a circular target DNA (Figure 1C) in a buffer
containing 20 mM HEPES pH 7.5, 10 mM DTT, 5 mM MgCl2,
4 mM ZnCl2, and 100 mM NaCl, in the absence of glycerol,
DMSO and PEG, which are required for integration with wild-
type HIV IN (Figure 1D). Concerted integration was readily
detected and activity was maximal at a protein to viral DNA ratio
of about 2:1. The panel on the left is stained with ethidium
Figure 4. EMSA of intasomes assembled with Sso7d-IN (Gly-11) and a 25 bp DNA substrate (FAM labeled U5-25). To prevent non-
specific DNA binding, 10 mg/ml of heparin was added to the reaction mixture after intasome assembly as well as into 3% agarose gels. A, Intasomes
assemble with Sso7d-IN (lane 3), but not with wild-type HIV-1 IN (lane 1) or the Sso7d domain alone (lane 2). B, Sso7d-IN specifically assembles
intasomes on LTR-U5 sequence (lane 1), but not on ‘‘CA/GT mut’’ (lane 2) or ‘‘3 bp mismatch’’ (lane 3) DNAs. In the ‘‘CA/GT mut’’ DNA, the conserved
‘‘CA’’ dinucleotide is replaced by ‘‘GT’’ (highlighted in the sequence). ‘‘3 bp mismatch’’ was prepared by replacing of ‘‘ACT’’ with ‘‘TGA’’ at the 59 end
of the non-joining strand.
doi:10.1371/journal.pone.0105078.g004
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PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e105078Figure 5. Size-exclusion chromatography of intasomes assembled with Sso7d-IN (Gly-11) and 25 bp DNA (U5-25 DNA). A, Elution
profile of intasomes on Superdex 200 2.3/30. The peak labeled free protein as expected elutes in the presence of zinc at a position consistent with a
tetramer of Sso7d-IN. The intasome peak elutes at greater than 400 kD relative to protein standards, which is greater than expected for monomeric
intasomes. B, Fractions 1 to 15 (F1–F15), corresponding to 13.75 min to 32.5 min elution time (highlighted with blue bar) were analyzed by SDS PAGE
(panel B) and 3% agarose gel electrophoresis (panel C), and visualized by silver staining and ethidium bromide staining, respectively. D, Fractions F5
to F20 (highlighted in red), corresponding to 18.75 min to 38.75 min elution time, were tested for strand transfer activity in the presence of Mg
2+ and
supercoiled plasmid DNA. Note that the bulk of strand transfer activity co-elutes with the protein-DNA complex at around 23–28 min elution time
(F8–F11). Concerted integration products are indicated by the arrow. The smear resulting from multiple concerted integration events is indicated by
the square brackets.
doi:10.1371/journal.pone.0105078.g005
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visualized. Interestingly, mutations in Sso7d that impair DNA
binding did not reduce the hyperactive phenotype (Figure S1).
Optimization of the Sso7d-IN construct and reaction
condition
The length of LTR-U5 DNA sequence was varied to maximize
the reaction efficiency (Figure 2A). Concerted integration was
Figure 6. Sso7d-IN is functional in virions. The assay is based on the ability of IN expressed as a Vpr fusion protein to transcomplement N/N
virus lacking a functional integrase. A, HIV-1 infectivity normalized to the level obtained with Vpr-IN complementation. The Vpr fusions used for
complementation and the infections that were conducted in the presence of RAL are indicated. Sso7d(mut) contains the mutations W24A and R43E
which abrogate DNA binding. Graphed are averages with standard deviation for n=3 (infections with RAL or Vpr-IN-D64A) or n=6 independent
experiments. B, Western blot of IN deletion mutant virus produced with indicated Vpr fusions probed for IN (left panel) and p24 (right panel). All Vpr-
IN constructs yielded similar levels of packaged IN protein. The anti-IN antibody 8E5 recognizes the C-terminus (262–271) of IN [18] while the anti-p24
was from Abcam.
doi:10.1371/journal.pone.0105078.g006
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37 bp was less efficient, perhaps due to the competition for the
fixed protein concentration in the reaction mixture. During
reaction optimization of Sso7d-IN, we noticed that substrates
containing the GC rich motif AGCGTGGGCG at the 59 end of
the non-joining strand had slightly greater activity (Figure S1), but
this phenomenon was not further explored. The length of the
linker between Sso7d and IN was also optimized (Figure 2B).
Fusion proteins with a glycine linker as short as 1 amino acid (Gly-
1) were capable of catalyzing concerted integration, but the
reaction was somewhat more efficient with longer linkers, likely the
result of greater flexibility between the domains, increasing
modestly from Gly-3 to Gly-11. Unless otherwise stated, Sso7d-
IN with an 11-glycine linker was used for the rest of the work. We
also found the strand transfer reaction was favored in 20–25%
glycerol, whereas PEG and DMSO, which stimulate the reaction
with wild-type IN, reduced the reaction efficiency with Sso7d-IN
(data not shown). Figure 2C shows concerted integration carried
out by the Sso7d-IN with an 11 amino acid linker and U5-25 in
the presence of 25% glycerol. The reaction is so efficient that the
entire supercoiled target DNA substrate is consumed. The smear
below the linear integration product results from multiple
concerted integration events on the same target (Figure 2D),
which is possible because the viral DNA ends are in large excess.
Sequence analysis of the concerted integration products
To test the fidelity of Sso7d-IN mediated strand transfer under
optimized in vitro conditions the linear DNA corresponding to
concerted integration products was isolated from an agarose gel,
cloned and sequenced. The majority of integration products
contained a 5 bp target site duplication (n=36), which is the
hallmark of correct HIV DNA integration. The other 10 clones
did not exhibit target-site duplications and instead had very short
deletions of target DNA sequence (Figure 3A). We believe these
products are explained by a second concerted integration event
occurring very close to the first integration site. In other words,
they are representative of the contaminating smear from just
below the linear product DNA excised from the agarose gel shown
in Figure 2C. Alignment of all the U5-target DNA junction
sequences recovered in our experiments (n=72) revealed a weak
bias in nucleotide content that is consistent with the observed
in vivo results [21] (Figure 3B).
Sso7d-IN forms stable intasomes with oligonucleotide
DNA
Previous experiments have shown that wild-type IN forms
intasomes with 1 kb viral DNA ends and that these intasomes
migrate as discrete bands within a native agarose gel [22].
However stable intasomes do not form with DNA shorter than a
few hundred base pairs. We therefore tested whether Sso7d-IN
forms intasomes with short DNA substrates. Gel-shift analysis
showed that Sso7d-IN does indeed assemble intasomes with a
25 bp DNA substrate (Figure 4A). The intasomes were assembled
in the presence of Ca
2+ which supports assembly of intasomes, but
not catalysis of DNA strand transfer [23,24]. Intasome assembly is
specific for the viral DNA sequence. Importantly, intasomes were
not formed when the conserved CA is mutated to GT or when a
3 bp mismatch is present at the viral DNA terminus (Figure 4B).
Intasomes assembled with Sso7d-IN, like PFV intasomes, are
stable to challenge with 1 M NaCl (data not shown).
Efficient strand transfer reactions with purified HIV-1
intasomes
Intasomes were purified from unreacted DNA substrate and
free protein by size exclusion chromatography on Superdex 200
(Figure 5A). As expected, the fractions corresponding to the
intasome peak contained both DNA substrate and Sso7d-IN
protein (Figure 5B and 5C). The purified intasomes carried out
highly efficient concerted integration in the presence of Mg
2+, with
minimal half-site integration events (Figure 5D). The smear below
the concerted integration product is the result of multiple
integrations within the same target DNA molecule.
Sso7d-IN activity in vivo
Can Sso7d-IN support integration of viral DNA in vivo?T o
answer this question we tested the ability of Vpr-Sso7d-IN fusion
protein to transcomplement a non-infectious virus that carries IN
active site mutations D64N/D116N (N/N) and a luciferase
reporter gene (Figure 6A). As expected (15), the N/N virus alone
supported an extremely low level of luciferase activity from
unintegrated DNA (,0.4% of the level of wild-type HIV-Luc
infection), which was not further affected by including the potent
integrase inhibitor RAL during the infection. The addition of Vpr-
IN significantly boosted N/N infectivity to approximately 58% of
the wild-type virus. Potent inhibition of this infection by RAL
proves that Vpr-IN transcomplementation required HIV-1 DNA
integration, which was also evident by the lack of complementa-
tion by a Vpr-IN mutant that carried the D64A active site
mutation. The function of Vpr-Sso7d-IN was reduced about four-
fold relative to wild-type IN. As RAL similarly inhibited this
infection, the Sso7d-IN protein is active in the context of HIV-1
infection. Mutations that reduced the binding of Sso7D to DNA
had little effect on the efficiency of integration, as is also observed
in vitro. Western blotting was utilized to visualize IN protein
content in virus preparations. To avoid potential misassignement
of the viral N/N active site mutant IN, pseudovirus for western
blotting was based on an IN deletion mutant construct. Vpr-
Sso7d-IN is packaged at comparable levels to that of Vpr-IN
(Figure 6B).
Discussion
Obtaining high-resolution structures of HIV-1 intasomes
remains an elusive goal. Such structures are required to
understand the detailed mechanism of action of inhibitors and
mutations that confer resistance. In the absence of structures of the
HIV complexes, models based on the PFV intasome structures are
the best available option [11–13]. These are likely to be quite
reliable in the immediate vicinity of the active site, but because of
the degree of sequence divergence, modeling regions further from
the active site presents challenges. The two main obstacles to high-
resolution structures of HIV-1 intasomes are the propensity of
them to aggregate and the requirement for several hundred bp
long DNA substrate for efficient assembly. The Sso7d-IN fusion
protein described here overcomes the requirement for long DNA
through allowing intasomes to assemble with an oligonucleotide
DNA substrate as well as improving the solubility of the complex.
By a combination of ion exchange and size-exclusion chromatog-
raphy we have purified HIV intasomes made with Sso7d-IN and
concentrated them to about 5 mg/ml in the presence of 0.5 M
NaCl (data not shown). However, there is still some heterogeneity
as judged by the shape of the peak eluted from size exclusion
columns (Figure 5) and atomic force microscopy (data not shown).
How does the Sso7d domain improve the concerted integration
activity and biophysical properties of HIV-1 IN? It would appear
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significantly diminished when the Sso7d domain contains muta-
tions that greatly reduce DNA binding (Figure S1). We favor the
hypothesis that Sso7d shields a surface on HIV-1 IN that is
responsible for unfavorable interactions that mediate aggregation
and non-productive intasome assembly. The hyperactive pheno-
type likely results from blocking the formation of nonproductive
complexes rather than directly ‘‘hyperactivating’’ the enzymatic
activity by classical means. This interpretation is consistent with
several other observations that are not easily explained. Wild-type
HIV-1 IN requires viral DNA several hundred base pairs in length
to efficiently assemble intasomes, even though footprinting shows
interaction with less than 20 terminal base pairs [22,25], consistent
with the crystal structure of the PFV intasome. Curiously, only one
of the two DNA molecules in the intasome needs to be long for
efficient assembly [26]. One possible explanation is that the DNA
bends back onto the intasome surface masking unfavorable
interactions. LEDGF/p75 may also perform a similar function
in vitro. LEDGF/p75 stimulates concerted integration with
oligonucleotide DNA substrate [27] by a mechanism that may
be distinct from its in vivo role of tethering intasomes to
chromatin.
Sso7d-IN is not hyperactive when incorporated into virions and
viral DNA integrates with several fold lower efficiency than with
wild-type IN. This is consistent with an in vitro role of Sso7d in
preventing aggregation and non-productive intasome assembly.
Since only one viral DNA is made per infecting virion and
therefore only a single intasome is assembled, aggregation of
intasomes is not an overarching issue and protein modifications
that lessen aggregation therefore do not confer an advantage.
Although the modified N-terminus hinders IN activity by
approximately 4-fold, Sso7d-IN importantly retains significant
function in the context of HIV-1 infection. Sso7d-IN is a step
forward towards high-resolution structural studies of HIV-1
intasomes, but further advances will likely be necessary before
this goal can be attained.
Supporting Information
Figure S1 Mutations on the DNA binding surface of
Sso7d do not diminish the hyperactive phenotype of
Sso7d-IN. Reactions were carried out with Sso7d-IN or
Sso7dmut-IN (W24A/R43E). The DNA substrates were 25 bp
of HIV-1 U5 terminal DNA sequence (U5) or the same DNA with
a GC rich motif at the 59 end of the non-transferred strand (see
Materials and Methods).
(PDF)
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